Snape Timothy J, Warr Tracy
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Lancashire, UK.
Brain Tumour Research Centre, University of Wolverhampton, Wolverhampton, UK.
Semin Pediatr Neurol. 2015 Mar;22(1):28-34. doi: 10.1016/j.spen.2014.12.003. Epub 2014 Dec 16.
Gliomas represent approximately 70% of all pediatric brain tumors, and most of these are of astrocytic lineage; furthermore, malignant or high-grade astrocytomas account for approximately 20% of pediatric astrocytoma. Treatment options for pediatric patients with glioma are limited. Although low-grade astrocytomas are relatively slow-growing tumors that can often be cured through surgical resection, a significant proportion of cases recur, as such, new treatments are desperately needed. This review covers the various approaches that are currently being made toward improving the prognosis of pediatric patients with glioma by pursuing pediatric-selective mutant drug targets with emerging small molecules.
神经胶质瘤约占所有儿童脑肿瘤的70%，其中大多数起源于星形胶质细胞谱系；此外，恶性或高级别星形细胞瘤约占儿童星形细胞瘤的20%。儿童神经胶质瘤患者的治疗选择有限。虽然低级别星形细胞瘤是生长相对缓慢的肿瘤，通常可通过手术切除治愈，但仍有很大比例的病例会复发，因此迫切需要新的治疗方法。本综述涵盖了目前通过利用新型小分子寻找儿科特异性突变药物靶点来改善儿童神经胶质瘤患者预后的各种方法。
